Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.13 by 10.22 percent. This is a 358.33 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $25.90 million which beat the analyst consensus estimate of $22.49 million by 15.15 percent. This is a 482.15 percent increase over sales of $4.45 million the same period last year.